Abstract
Background. Liver is the commonest site for metastasis in patients with neuroendocrine tumour (NET). A vast majority of treatment strategies including liver directed nonsurgical therapy, liver directed surgical therapy, and nonliver directed therapy have been proposed. In this study we aim to investigate the outcome of liver resection in neuroendocrine tumour liver metastases (NELM). Method. 293 patients had hepatectomy for liver metastasis in our hospital between June 1996 and December 2010. Twelve patients were diagnosed to have NET in their final pathology and their data were reviewed. Results. The median ages of the patients were 48.5 years (range 20–71 years). Eight of the patients received major hepatectomy. Four patients received minor hepatectomy. The median operation time was 418 minutes (range 195–660 minutes). The median tumor size was 8.75 cm (range 0.9–21 cm). There was no hospital mortality. The overall one-year and three-year survivals were 91.7% and 55.6%. The one-year and three-year disease-free survivals were 33.3% and 16.7%. Conclusion. Hepatectomy is an effective and safe treatment for NELM. Reasonable outcome on long term overall survival and disease-free survival can be achieved in this group of patients with a low morbidity rate.
Highlights
Neuroendocrine tumours (NETs) comprise a wide range of neoplasm which originates from cells of nervous and endocrine systems
Liver resection was considered to be the most effective treatment for neuroendocrine tumour liver metastases (NELM) in terms of survival, not every patient was considered for hepatectomy due to the potential complications and even mortality
Hepatectomy for NELM had not been supported by large scale studies
Summary
Neuroendocrine tumours (NETs) comprise a wide range of neoplasm which originates from cells of nervous and endocrine systems. The most common sites of the disease include the small bowel, large bowel, and the pancreas. It can arise from other parts of the body. Liver is the most common site of metastases for gastrointestinal NETs. Upon the first diagnosis, 56%–93% patients were found to have synchronous neuroendocrine liver metastases (NELM) together with a primary tumour [1]. Liver resection was considered to be the most effective treatment for NELM in terms of survival, not every patient was considered for hepatectomy due to the potential complications and even mortality. Liver is the commonest site for metastasis in patients with neuroendocrine tumour (NET). In this study we aim to investigate the outcome of liver resection in neuroendocrine tumour liver metastases (NELM). Reasonable outcome on long term overall survival and disease-free survival can be achieved in this group of patients with a low morbidity rate
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
